Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
NCT06087536Phase 2Recruiting
- Sponsor
- Omnix Medical
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of OMN-6 in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), Acinetobacter baumannii infection, sponsored by Omnix Medical. Started May 2026; status: recruiting.
02
Drugs
OMN-6
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT06087536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087536.